Women's health research highlights the role of molecular testing in precision medicine
Molecular diagnostic approaches are expanding what information is available for clinicians and laboratory professionals, including uncovering antimicrobial resistance, identifying pathogens missed by conventional methods, revealing cancer recurrence risks and characterizing complex tumor biology.
Recent studies presented at the Association for Molecular Pathology (AMP) 2026 Annual Meeting & Expo in Seattle highlight the growing role of molecular testing in precision medicine, particularly in women's healthcare. Two noteworthy studies were highlighted: one focusing on the utility of molecular testing in diagnosing and treating Mycoplasma genitalium (MG) infections, and another examining the potential of DNA methylation profiling to predict recurrence risk in a specific type of endometrial cancer.
The MG study, conducted by researchers at Unified Women's Healthcare and Alline, analyzed over 121,000 vaginal swab specimens. Of the 4,605 MG-positive cases, 41.5% exhibited resistance to macrolide antibiotics, a critical finding for guiding treatment options. By implementing automated reflex testing, the researchers achieved a median turnaround time of four days, demonstrating the feasibility of CDC-recommended resistance-guided treatment in high-volume women's health settings.
This research underscores the importance of molecular diagnostics in tailoring antibiotic therapies to individual patient needs.
In the oncology study led by Matthew Zunitch at the University of California, San Francisco, researchers profiled DNA methylation patterns in 219 low-grade, limited-stage, copy number-low endometrioid adenocarcinoma tumors. This analysis revealed distinct methylation signatures that correlated with recurrence risk, as well as differential enrichment of certain genetic mutations (CTNNB1 and DICER1) and copy number gains in chromosome 1q.
These findings suggest that epigenetic profiling could help distinguish recurrence risk among patients whose tumors share similar clinical and pathologic characteristics, paving the way for more personalized endometrial cancer treatment strategies.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
